Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
| Country | Israel |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Motti Farbstein |
Contact Details
Address: 26 Ben Gurion Street Ramat Gan, 5257346 Israel | |
| Phone | 972 3 924 1114 |
| Website | canfite.com |
Stock Details
| Ticker Symbol | CANF |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001536196 |
| CUSIP Number | 13471N201 |
| ISIN Number | US13471N3008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Motti Farbstein | Chief Executive Officer and Chief Financial and Operating Officer |
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer and Executive Chairperson |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development |
| Dr. Ilan Cohn Ph.D. | Co-Founder and Director |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board and Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Oct 18, 2024 | 6-K | Report of foreign issuer |
| Oct 9, 2024 | 6-K | Report of foreign issuer |
| Sep 24, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 6, 2024 | EFFECT | Notice of Effectiveness |
| Sep 6, 2024 | 424B3 | Prospectus |